indomethacin has been researched along with No-Reflow Phenomenon in 1 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
No-Reflow Phenomenon: Markedly reduced or absent REPERFUSION in an infarct zone following the removal of an obstruction or constriction of an artery.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiao, Q | 1 |
| Ke, Q | 1 |
| Li, W | 1 |
| Jin, M | 1 |
| Luo, Y | 1 |
| Zhang, L | 1 |
| Yang, D | 1 |
| Zhang, X | 1 |
1 other study available for indomethacin and No-Reflow Phenomenon
| Article | Year |
|---|---|
Effect of inflammatory factor-induced cyclo-oxygenase expression on the development of reperfusion-related no-reflow phenomenon in acute myocardial infarction.
Topics: Acute Disease; Animals; C-Reactive Protein; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhib | 2015 |